Assessing the Role of Daptomycin as Antibiotic Therapy for Staphylococcal Prosthetic Joint Infection

Carli, Alberto V.; Miller, Andy O.; Kapadia, Milan; Chiu, Yu-fen; Westrich, Geoffrey H.; Brause, Barry D.; Henry, Michael W.

doi:https://doi.org/10.7150/jbji.41278

Articles | Volume 5, issue 2

Article
Metrics
Related articles

Articles | Volume 5, issue 2

https://doi.org/10.7150/jbji.41278

Articles | Volume 5, issue 2

Article
Metrics
Related articles

Original full-length article

30 Mar 2020

Original full-length article |

| 30 Mar 2020

Assessing the Role of Daptomycin as Antibiotic Therapy for Staphylococcal Prosthetic Joint Infection

Alberto V. Carli, Andy O. Miller, Milan Kapadia, Yu-fen Chiu, Geoffrey H. Westrich, Barry D. Brause, and Michael W. Henry

Alberto V. Carli

CORRESPONDING AUTHOR

Hospital for Special Surgery, Division of Adult Reconstruction & Joint Replacement, 535 East 70th Street, New York, NY 10065, USA

Andy O. Miller

Hospital for Special Surgery, Infectious Disease Division, 535 East 70th Street, New York, NY 10065, USA

Milan Kapadia

Hospital for Special Surgery, Infectious Disease Division, 535 East 70th Street, New York, NY 10065, USA

Yu-fen Chiu

Hospital for Special Surgery, Division of Adult Reconstruction & Joint Replacement, 535 East 70th Street, New York, NY 10065, USA

Geoffrey H. Westrich

Hospital for Special Surgery, Division of Adult Reconstruction & Joint Replacement, 535 East 70th Street, New York, NY 10065, USA

Barry D. Brause

Hospital for Special Surgery, Infectious Disease Division, 535 East 70th Street, New York, NY 10065, USA

Michael W. Henry

Hospital for Special Surgery, Infectious Disease Division, 535 East 70th Street, New York, NY 10065, USA

Cited articles

Kapadia BH, Berg RA, Daley JA, Fritz J, Bhave A, Mont MA. Periprosthetic joint infection. Lancet Lond Engl. 2016;387(10016):386–394. doi:10.1016/S0140- 6736(14)61798-0.

Berend KR, Lombardi AV, Morris MJ, Bergeson AG, Adams JB, Sneller MA. Two-stage treatment of hip periprosthetic joint infection is associated with a high rate of infection control but high mortality. Clin Orthop. 2013;471(2):510–518. doi:10.1007/s11999-012-2595-x. [PMC free article]

Geipel U. Pathogenic organisms in hip joint infections. Int J Med Sci. 2009;6(5):234–240. [PMC free article]

Drago L, De Vecchi E, Bortolin M, Zagra L, Romanò CL, Cappelletti L. Epidemiology and Antibiotic Resistance of Late Prosthetic Knee and Hip Infections. J Arthroplasty. 2017;32(8):2496–2500. doi:10.1016/j.arth.2017.03.005.

Ravi S, Zhu M, Luey C, Young SW. Antibiotic resistance in early periprosthetic joint infection. ANZ J Surg. 2016;86(12):1014–1018. doi:10.1111/ans.13720.

Edelstein AI, Okroj KT, Rogers T, Della Valle CJ, Sporer SM. Nephrotoxicity After the Treatment of Periprosthetic Joint Infection With Antibiotic-Loaded Cement Spacers. J Arthroplasty. 2018;33(7):2225–2229. doi:10.1016/j.arth.2018. 02.012.

Patel RA, Baker HP, Smith SB. Acute Renal Failure due to a Tobramycin and Vancomycin Spacer in Revision Two-Staged Knee Arthroplasty. Case Rep Nephrol. 2018;2018:6579894.. doi:10.1155/2018/6579894. [PMC free article]

Tótoli EG, Garg S, Salgado HRN. Daptomycin: Physicochemical, Analytical, and Pharmacological Properties. Ther Drug Monit. 2015;37(6):699–710. doi:10.1097/FTD.0000000000000222.

Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact. 2004;150(2):137–147. doi:10.1016/j.cbi.2004.08.004.

Kullar R, McClellan I, Geriak M, Sakoulas G. Efficacy and safety of daptomycin in patients with renal impairment: A multicenter retrospective analysis. Pharmacotherapy. 2014;34(6):582–589. doi:10.1002/phar.1413.

Claeys KC, Zasowski EJ, Casapao AM. et al. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother. 2016;60(10):5841–5848. doi:10.1128/AAC.00227- 16. [PMC free article]

Hall Snyder AD, Vidaillac C, Rose W, McRoberts JP, Rybak MJ. Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm. Infect Dis Ther. 2015;4(1):51–65. doi:10.1007/s40121-014-0055-5. [PMC free article]

Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Crémieux A-C. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55(10):4589–4593. doi:10.1128/AAC. 00675-11. [PMC free article]

Garrigós C, Murillo O, Euba G. et al. Efficacy of Usual and High Doses of Daptomycin in Combination with Rifampin versus Alternative Therapies in Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(12):5251–5256. doi:10.1128/AAC. 00226-10. [PMC free article]

John A-K, Baldoni D, Haschke M. et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: Importance of combination with rifampin. Antimicrob Agents Chemother. 2009;53(7):2719–2724. doi:10.1128/AAC.00047-09. [PMC free article]

Browne C, Muszbek N, Chapman R. et al. Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin. Int J Antimicrob Agents. 2016;47(5):357–361. doi:10.1016/j.ijantimicag.2016.02.006.

Bhavnani SM, Prakhya A, Hammel JP, Ambrose PG. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin- resistant Staphylococcus aureus bacteremia and/or endocarditis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;49(5):691–698. doi:10.1086/604710.

Joseph C, Robineau O, Titecat M. et al. Daptomycin versus Vancomycin as Post-Operative Empirical Antibiotic Treatment for Prosthetic Joint Infections: A Case-Control Study. J Bone Jt Infect. 2019;4(2):72–75. doi:10.7150/jbji.22118. [PMC free article]

Chang Y-J, Lee MS, Lee C-H, Lin P-C, Kuo F-C. Daptomycin treatment in patients with resistant staphylococcal periprosthetic joint infection. BMC Infect Dis. 2017;17(1):736.. doi:10.1186/s12879-017-2842-6. [PMC free article]

Montange D, Berthier F, Leclerc G. et al. Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob Agents Chemother. 2014;58(7):3991–3996. doi:10.1128/AAC.02344-14. [PMC free article]

Parvizi J, Gehrke T. Definition of Periprosthetic Joint Infection. J Arthroplasty. 2014;29(7):1331.. doi:10.1016/j.arth.2014.03.009.

Quan H, Li B, Couris CM. et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq433.

Diaz-Ledezma C, Higuera CA, Parvizi J. Success after treatment of periprosthetic joint infection: A Delphi-based international multidisciplinary consensus. Clin Orthop. 2013;471(7):2374–2382. doi:10.1007/s11999-013-2866-1. [PMC free article]

Seaton RA, Gonzalez-Ruiz A, Cleveland KO, Couch KA, Pathan R, Hamed K. Real-world daptomycin use across wide geographical regions: Results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob. 2016;15:18.. doi:10.1186/s12941-016-0130-8. [PMC free article]

Kim PW, Sorbello AF, Wassel RT, Pham TM, Tonning JM, Nambiar S. Eosinophilic pneumonia in patients treated with daptomycin: Review of the literature and US FDA adverse event reporting system reports. Drug Saf. 2012;35(6):447–457. doi:10.2165/11597460-000000000-00000.

Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, Daptomycin 98-01, 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;38(12):1673–1681. doi:10.1086/420818.

Kostrominova TY, Coleman S, Oleson FB, Faulkner JA, Larkin LM. Effect of daptomycin on primary rat muscle cell cultures in vitro. In Vitro Cell Dev Biol Anim. 2010;46(7):613–618. doi:10.1007/s11626-010-9311-5.

Hohenegger M. Drug induced rhabdomyolysis. Curr Opin Pharmacol. 2012;12(3):335–339. doi:10.1016/j.coph.2012.04.002. [PMC free article]

Odum SM, Fehring TK, Lombardi AV. et al. Irrigation and debridement for periprosthetic infections: Does the organism matter? J Arthroplasty. 2011;26(6 Suppl):114–118. doi:10.1016/j.arth.2011.03.031.

Urish KL, Bullock AG, Kreger AM. et al. A Multicenter Study of Irrigation and Debridement in Total Knee Arthroplasty Periprosthetic Joint Infection: Treatment Failure Is High. J Arthroplasty. 2018;33(4):1154–1159. doi:10.1016/ j.arth.2017.11.029. [PMC free article]

Löwik CAM, Jutte PC, Tornero E. et al. Predicting Failure in Early Acute Prosthetic Joint Infection Treated With Debridement, Antibiotics, and Implant Retention: External Validation of the KLIC Score. J Arthroplasty. 2018;33(8):2582–2587. doi:10.1016/j.arth.2018.03.041.

Tertiary care centre adherence to unified guidelines for management of periprosthetic joint infections. A gap analysis. https://www.ncbi.nlm.nih. gov/pmc/articles/PMC5785287/. Accessed February 19. 2020.

Kuo F-C, Yen S-H, Peng K-T, Wang J-W, Lee MS. Methicillin-resistant Staphylococcal periprosthetic joint infections can be effectively controlled by systemic and local daptomycin. BMC Infect Dis. 2016;16:48.. doi:10.1186/ s12879-016-1366-9. [PMC free article]

Zimmerli W, Sendi P. Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections. Antimicrob Agents Chemother. 2019. 63(2). doi:10.1128/AAC.01746-18. [PMC free article] [PubMed]